Therapeutic management of fibrosis in systemic sclerosis patients - an analysis from the Swiss EUSTAR cohort
CONCLUSION: Overall, in Switzerland, a wide range of medications is prescribed for systemic sclerosis patients. This includes modern, targeted treatments for which randomised controlled clinical trial have been recently reported.PMID:38579324 | DOI:10.57187/s.3630 (Source: Swiss Medical Weekly)
Source: Swiss Medical Weekly - April 5, 2024 Category: General Medicine Authors: Kevin Windirsch Suzana Jordan Mike Oliver Becker Cosimo Bruni Rucsandra Dobrota Muriel Elhai Ion-Alexandru Garaiman Carmen-Marina Mihai Michele Iudici Paul Hasler Camillo Ribi Britta Maurer Armando Gabrielli Anna-Maria Hoffmann-Vold Oliver Distler Source Type: research
Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma
ConclusionsLenalidomide appears to be a promising therapeutic agent that offers the possibility of a novel combination of chemotherapy free regimen for patients with B-cell non-Hodgkin lymphoma. (Source: Hormones and Cancer)
Source: Hormones and Cancer - April 5, 2024 Category: Cancer & Oncology Source Type: research
Case report: EBV-related eye orbits and sinuses lymphohistiocytic infiltration responsive to rituximab in a patient with X lymphoproliferative syndrome type 1
ConclusionWe described an unusual presentation of incomplete HLH in a patient affected with XLP1: an EBV-driven infiltration of the orbits and paranasal sinuses. This led us to a challenging differential diagnosis of lymphoma-associated hemophagocytic syndrome, which can be frequently observed in patients with XLP1. Considering the extremely poor prognosis of this clinical finding, we sought for a prompt diagnosis and managed to obtain it and to immediately establish the right treatment on the basis of the pathological finding. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - April 3, 2024 Category: Allergy & Immunology Source Type: research
Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies
Idiopathic inflammatory myopathies (IIM) represent a rare and heterogenous group diseases, and their treatment is not fully defined yet. According to previous small case series, the combination of mycophenolat... (Source: Arthritis Research and Therapy)
Source: Arthritis Research and Therapy - April 3, 2024 Category: Rheumatology Authors: Corrado Campochiaro, Nicola Farina, Giacomo De Luca, Veronica Batani, Giorgia Trignani, Davide Vignale, Anna Palmisano, Marco Matucci-Cerinic and Lorenzo Dagna Tags: Research Source Type: research
Combined rituximab and belimumab to treat recalcitrant epidermolysis bullosa aquisita associated with systemic lupus erythematosus
Br J Dermatol. 2024 Apr 2:ljae141. doi: 10.1093/bjd/ljae141. Online ahead of print.NO ABSTRACTPMID:38561894 | DOI:10.1093/bjd/ljae141 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - April 2, 2024 Category: Dermatology Authors: Thomas J Tull Emma C Benton Kristina Semkova Natalie A Watson John B Mee Begona Lopez Jane Setterfield Barbara Carey Sajjad Ajmad Scott J Robbie Richard W Groves Giovanni Sanna David P D'Cruz Source Type: research
Combined rituximab and belimumab to treat recalcitrant epidermolysis bullosa aquisita associated with systemic lupus erythematosus
Br J Dermatol. 2024 Apr 2:ljae141. doi: 10.1093/bjd/ljae141. Online ahead of print.NO ABSTRACTPMID:38561894 | DOI:10.1093/bjd/ljae141 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - April 2, 2024 Category: Dermatology Authors: Thomas J Tull Emma C Benton Kristina Semkova Natalie A Watson John B Mee Begona Lopez Jane Setterfield Barbara Carey Sajjad Ajmad Scott J Robbie Richard W Groves Giovanni Sanna David P D'Cruz Source Type: research
Combined rituximab and belimumab to treat recalcitrant epidermolysis bullosa aquisita associated with systemic lupus erythematosus
Br J Dermatol. 2024 Apr 2:ljae141. doi: 10.1093/bjd/ljae141. Online ahead of print.NO ABSTRACTPMID:38561894 | DOI:10.1093/bjd/ljae141 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - April 2, 2024 Category: Dermatology Authors: Thomas J Tull Emma C Benton Kristina Semkova Natalie A Watson John B Mee Begona Lopez Jane Setterfield Barbara Carey Sajjad Ajmad Scott J Robbie Richard W Groves Giovanni Sanna David P D'Cruz Source Type: research
Statin-induced immune-mediated necrotizing myopathy with concomitant increase of anti-HMGCR and anti-ACHR antibodies
We present a case of a patient with a severe phenotype of the disease that was found to have an increase in anti-HMGCR and anti-ACHR antibodies. A potential association between these antibodies have not been previously described. A 67-year-old male with hyperlipidemia, who was recently initiated on atorvastatin therapy, presented to the ED with progressive muscle weakness. Within a few days of admission, the patient developed complete flaccid paralysis and respiratory distress requiring intubation. The patient ’s CK was elevated to 24,000 and there was an increase of anti-HMGCR and anti-ACHR antibodies. Impressions from ...
Source: Rheumatology International - April 2, 2024 Category: Rheumatology Source Type: research
Pancytopenia with aplastic anemia in systemic lupus erythematosus: case series and literature review
We report two cases of SLE patients who presented with pancytopenia, with bone marrow biopsy confirmed AA. One case was treated with cyclophosphamide but unfortunately succumbed to Acute Respiratory Distress Syndrome (ARDS), while the other case was managed with rituximab with a good response. Interestingly, both patients were on azathioprine before the diagnosis of AA. A comprehensive search for reported cases of AA in PubMed, Scopus, and the Directory of Open Access Journals databases was performed to enhance the understanding of the diagnostic and management challenges associated with AA in SLE, facilitating ongoing exp...
Source: Rheumatology International - April 2, 2024 Category: Rheumatology Source Type: research
Progressive demyelinating polyneuropathy after hematopoietic cell transplantation in metachromatic leukodystrophy: a case series
AbstractMetachromatic leukodystrophy (MLD) is a neuro-metabolic disorder due to arylsulfatase A deficiency, causing demyelination of the central and peripheral nervous system. Hematopoietic cell transplantation (HCT) can provide a symptomatic and survival benefit for pre-symptomatic and early symptomatic patients by stabilizing CNS disease. This case series, however, illustrates the occurrence of severely progressive polyneuropathy shortly after HCT in two patients with late-infantile, one with late-juvenile, and one with adult MLD, leading to the inability to walk or sit without support. The patients had demyelinating pol...
Source: Journal of Neurology - April 2, 2024 Category: Neurology Source Type: research
Mycophenolate mofetil/rituximab/romiplostim
(Source: Reactions Weekly)
Source: Reactions Weekly - April 1, 2024 Category: Drugs & Pharmacology Source Type: research
Bendamustine/Rituximab
(Source: Reactions Weekly)
Source: Reactions Weekly - April 1, 2024 Category: Drugs & Pharmacology Source Type: research
Antibiotics/bendamustine/rituximab
(Source: Reactions Weekly)
Source: Reactions Weekly - April 1, 2024 Category: Drugs & Pharmacology Source Type: research
Rituximab
(Source: Reactions Weekly)
Source: Reactions Weekly - April 1, 2024 Category: Drugs & Pharmacology Source Type: research
Cardiac Tamponade Associated to an Early EBV-Induced Lymphoma After Heart Transplantation: A Case Report
We present a 2 month cardiac transplant patient who developed an EBV-associated primo infection PTLD, complicated of massive pericardial effusion, successfully treated with rituximab and combination chemotherapy. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , C. Dewachter, C. Stefanidis, A. Wolfrom, J. Vachiery, A. Roussoulieres Source Type: research
